Adoptive cell therapy for Melanoma using tumour infiltrating lymphocytes: John Bridgeman
4 意见
• 07/30/23
0
0
嵌入
A look at the use of TIL in Melanoma and future TIL engineering strategies. John Bridgeman is the Director of Cell Therapy Research at Immetacyte Ltd
显示更多
脸书评论
SORT BY-
热门评论
-
最新评论